Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan

被引:0
|
作者
Shibata, Yasushi [1 ]
Sato, Hiroshige [2 ]
Sato, Akiko [3 ]
Harada, Yoichi [4 ]
机构
[1] Univ Tsukuba, Mito Med Ctr, Dept Neurosurg, Mito 3100015, Japan
[2] Sato Clin Internal Med & Neurosurg, Dept Neurosurg, Moriya, 6750115, Japan
[3] Sato Clin Internal Med & Neurosurg, Dept Neurol, Moriya 3020117, Japan
[4] Mito Brain Heart Ctr, Dept Neurosurg, Mito 3100004, Japan
来源
NEUROLOGY INTERNATIONAL | 2024年 / 16卷 / 03期
关键词
migraine; triptan; lasmiditan; step care; CGRP;
D O I
10.3390/neurolint16030048
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The combined use of lasmiditan and triptan is unexplored in medical literature. This study aimed to investigate whether the intake of lasmiditan following triptan improves migraine pain. Following triptan intake, if headache relief was less than 50% at 1 h, patients took 50 mg of lasmiditan within 2 h of migraine onset. Patients recorded headache intensity and adverse events (AEs) caused by lasmiditan at 1, 2, and 4 h after the intake of an additional 50 mg of lasmiditan. A significant reduction in pain scale was observed post 50 mg lasmiditan intake (p < 0.001, t-test). Pain relief was reported for 32 migraine attacks (80%) at 1 h after additional lasmiditan intake. Although AEs were observed in 63% of the patients who took an additional lasmiditan, most were mild and resolved 1 h after lasmiditan intake. Our study revealed the significant headache relief provided by an additional lasmiditan for patients who did not achieve satisfactory results following initial triptan intake for treating migraine. The AEs associated with this treatment strategy were mild and lasted for a short time. This study suggested that the combination of triptan and lasmiditan is promising for the treatment of migraine and should be studied in a randomized placebo-controlled trial.
引用
收藏
页码:643 / 652
页数:10
相关论文
共 50 条
  • [41] Newer Horizon for Treatment of Acute Attack of Migraine: Lasmiditan and Ubrogepant
    Maitra, Arpita
    Mukhopadhyay, Sabyasachi
    Das, Abhijit
    Choudhury, Shouvik
    NEUROLOGY INDIA, 2021, 69 (06) : 1759 - 1762
  • [42] The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
    Doty, Erin G.
    Hauck, Paula M.
    Krege, John H.
    Komori, Mika
    Hake, Ann M.
    Dong, Yan
    Lipton, Richard B.
    CNS DRUGS, 2022, 36 (07) : 771 - 783
  • [43] Budget Impact of Lasmiditan for the Acute Treatment of Migraine in the United States
    Milev, S.
    Pohl, G. M.
    Sun, A.
    Mason, O.
    Njuguna, N.
    Loo, L.
    HEADACHE, 2020, 60 : 64 - 64
  • [44] Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review
    Beauchene, Juliana K.
    Levien, Terri L.
    JOURNAL OF PHARMACY TECHNOLOGY, 2021, 37 (05) : 244 - 253
  • [45] Budget impact of lasmiditan for the acute treatment of migraine in the United States
    Milev, Sandra
    Pohl, Gerhardt
    Sun, Ariel
    Mason, Oksana
    Njuguna, Nancy
    Loo, Li Shen
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (12): : 1714 - 1723
  • [46] ACUTE TREATMENT OF MIGRAINE ATTACKS
    FERRARI, MD
    HAAN, J
    CURRENT OPINION IN NEUROLOGY, 1995, 8 (03) : 237 - 242
  • [47] TREATMENT OF ACUTE MIGRAINE ATTACKS
    WILKINSON, M
    HEADACHE, 1976, 15 (04): : 291 - 292
  • [48] The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
    Erin G. Doty
    Paula M. Hauck
    John H. Krege
    Mika Komori
    Ann M. Hake
    Yan Dong
    Richard B. Lipton
    CNS Drugs, 2022, 36 : 771 - 783
  • [49] TREATMENT OF MIGRAINE ATTACKS WITH SUMATRIPTAN
    FERRARI, MD
    NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05): : 316 - 321
  • [50] SUMATRIPTAN IN THE TREATMENT OF MIGRAINE ATTACKS
    NAPPI, G
    MICIELI, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1993, 53 (05): : 599 - 602